全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

以吞咽困难起病的可疑吉兰–巴雷综合征1例
A Case of Suspected Guillain-Barré Syndrome Starting with Dysphagia

DOI: 10.12677/jcpm.2025.42201, PP. 464-467

Keywords: 吞咽困难,周围神经病,吉兰–巴雷综合征,免疫治疗
Dysphagia
, Peripheral Neuropathy, Guillain-Barré Syndrome, Immunotherapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

本文报道一例75岁,老年男性,前驱呼吸道感染后出现不明原因吞咽困难,结合查体、脑脊液检查、肌电图后拟诊为吉兰–巴雷综合征(Guillain-Barré syndrome, GBS),予以血浆置换后出现严重过敏反应,患者相关症状未见明显改善。该病例为脑神经受损起病的不典型病例,自身免疫性周围神经病诊断明确,但患者无肌无力表现,予以血浆置换后出现严重过敏反应且疗效欠佳,仍需进一步鉴别诊断。而免疫性周围神经病变治疗方案多为血浆置换和静脉注射免疫球蛋白等传统免疫治疗,特异性差,需要更具有特异性的新兴免疫疗法来优化疗效,改善预后。
This paper reports the case of a 75-year-old man with unexplained dysphagia after antecedent respiratory tract infection, which was proposed to be diagnosed as Guillain-Barré syndrome (GBS) after combining physical examination, cerebrospinal fluid examination, and electromyography, and a severe anaphylactic reaction occurred after plasma exchange, and the patient’s related symptoms did not show significant improvement. This is an atypical case with brain nerve damage, and the diagnosis of autoimmune peripheral neuropathy is clear, but the patient did not have muscle weakness, and suffered a severe allergic reaction after plasma exchange with poor efficacy, so further differential diagnosis is still needed. The treatment options for autoimmune peripheral neuropathy are mostly traditional immunotherapy such as plasma exchange and intravenous immunoglobulin, which have poor specificity, and newer immunotherapies with more specificity are needed to optimize the efficacy and improve the prognosis.

References

[1]  van Doorn, P.A., Van den Bergh, P.Y.K., Hadden, R.D.M., Avau, B., Vankrunkelsven, P., Attarian, S., et al. (2023) European Academy of Neurology/peripheral Nerve Society Guideline on Diagnosis and Treatment of Guillain-Barré Syndrome. European Journal of Neurology, 30, 3646-3674.
https://doi.org/10.1111/ene.16073
[2]  中国吞咽障碍康复评估与治疗专家共识组. 中国吞咽障碍评估与治疗专家共识(2017年版)第一部分 评估篇[J]. 中华物理医学与康复杂志, 2017, 39(12): 881-892.
[3]  Eftimov, F., Lucke, I.M., Querol, L.A., Rajabally, Y.A. and Verhamme, C. (2020) Diagnostic Challenges in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Brain, 143, 3214-3224.
https://doi.org/10.1093/brain/awaa265
[4]  Leonhard, S.E., Papri, N., Querol, L., Rinaldi, S., Shahrizaila, N. and Jacobs, B.C. (2024) Guillain-Barré Syndrome. Nature Reviews Disease Primers, 10, Article No. 97.
https://doi.org/10.1038/s41572-024-00580-4
[5]  van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B.C. and van Doorn, P.A. (2014) Guillain-Barré Syndrome: Pathogenesis, Diagnosis, Treatment and Prognosis. Nature Reviews Neurology, 10, 469-482.
https://doi.org/10.1038/nrneurol.2014.121
[6]  Rajabally, Y.A. and Uncini, A. (2012) Outcome and Its Predictors in Guillain-Barré Syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 83, 711-718.
https://doi.org/10.1136/jnnp-2011-301882
[7]  Goodfellow, J.A. and Willison, H.J. (2016) Guillain-Barré Syndrome: A Century of Progress. Nature Reviews Neurology, 12, 723-731.
https://doi.org/10.1038/nrneurol.2016.172
[8]  Kesici, S., Tanyıldız, M., Yetimakman, F. and Bayrakci, B. (2019) A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method. Journal of Child Neurology, 34, 277-283.
https://doi.org/10.1177/0883073819826225
[9]  Davidson, A.I., Halstead, S.K., Goodfellow, J.A., Chavada, G., Mallik, A., Overell, J., et al. (2017) Inhibition of Complement in Guillain-Barré Syndrome: The ICA-GBS Study. Journal of the Peripheral Nervous System, 22, 4-12.
https://doi.org/10.1111/jns.12194
[10]  Kuwabara, S., Kusunoki, S., Kuwahara, M., Yamano, Y., Nishida, Y., Ishida, H., et al. (2024) Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Journal of the Peripheral Nervous System, 29, 339-349.
https://doi.org/10.1111/jns.12646
[11]  Sprenger-Svačina, A., Svačina, M.K.R., Gao, T., Zhang, G. and Sheikh, K.A. (2024) Emerging Treatment Landscape for Guillain-Barré Syndrome (GBS): What’s New? Expert Opinion on Investigational Drugs, 33, 881-886.
https://doi.org/10.1080/13543784.2024.2377323
[12]  Zhang, H., Ma, J., Feng, Y., Ma, H., Liu, D., Pang, X., et al. (2024) Efgartigimod in the Treatment of Guillain-Barré Syndrome. Journal of Neurology, 271, 3506-3511.
https://doi.org/10.1007/s00415-024-12321-4

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133